Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

Abdul Razak, Albiruni RAlbiruni RAbdul RazakBauer, SebastianSebastianBauerSuarez, CristinaCristinaSuarezCHIA-CHI LINQuek, RichardRichardQuekHütter-Krönke, Marie LuiseMarie LuiseHütter-KrönkeCubedo, RicardoRicardoCubedoFerretti, StephaneStephaneFerrettiGuerreiro, NelsonNelsonGuerreiroJullion, AstridAstridJullionOrlando, Elena JElena JOrlandoClementi, GiorgiaGiorgiaClementiSand Dejmek, JannaJannaSand DejmekHalilovic, EnsarEnsarHalilovicFabre, ClaireClaireFabreBlay, Jean-YvesJean-YvesBlayItaliano, AntoineAntoineItaliano2024-01-122024-01-122022-03-1510780432https://scholars.lib.ntu.edu.tw/handle/123456789/638441Well-differentiated (WDLPS) and dedifferentiated (DDLPS) liposarcoma are characterized by co-amplification of the murine double minute-2 (MDM2) and cyclin-dependent kinase-4 (CDK4) oncogenes. Siremadlin, a p53-MDM2 inhibitor, was combined with ribociclib, a CDK4/6 inhibitor, in patients with locally advanced/metastatic WDLPS or DDLPS who had radiologically progressed on, or despite, prior systemic therapy.en[SDGs]SDG3Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Studyjournal article10.1158/1078-0432.CCR-21-1291349210242-s2.0-85126388934https://api.elsevier.com/content/abstract/scopus_id/85126388934